Yoon Ji Choi - Concepedia

Author

Yoon Ji Choi

Korea University ORCID

Also Known As

Choi Y, Wonyoung Choi, Y Choi, Y J Choi, Y. Choi, Y.-J. Choi, Y.J. Choi, YOON JI CHOI, Yoon J CHOI, Yoon J. Choi

198

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Korea University Korea University Medical Center Seoul National University University of Ulsan Asan Medical Center

About

Yoon Ji Choi is an author at Korea University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	1.1K
2	Health Sciences	5	5	726
3	Engineering	4	4	89
4	Public Health	1	1	13
5	Biochemistry	1	1	23

Yoon Ji Choi

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors Hyeyoon Chang, Jung Sun Kim, Yoon Ji Choi, OncoTargets and Therapy	2017	58
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment Xiao–Tang Kong, Nhung Nguyen, Yoon Ji Choi, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyRadiation MedicineRadiation TherapyMedicineBortezomib Combined	2018	57
Association between hand grip strength and impaired health-related quality of life in Korean cancer survivors: a cross-sectional study Jeongki Paek, Yoon Ji Choi BMJ Open	2019	54
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib Y-K. Kang, Changhoon Yoo, B-Y. Ryoo, British Journal of Cancer	2013	53
Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer Myung Han Hyun, Jae Sook Sung, Eun Joo Kang, Oncotarget PathologyNsclc Patient PrognosisCancer DetectionPatient SurvivalDna Quantification	2017	52
Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment Pasi A. Jänne, Frédéric Bigot, Kyriakos P. Papadopoulos, Molecular Cancer Therapeutics Preliminary SafetyPharmacotherapyTumor BiologyMolecular PharmacologyReceptor Tyrosine Kinase	2023	50
Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism Eun Su Jeon, Il Hwan Lee, Soon Chul Heo, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids A549 Human AdenocarcinomaAngiogenesisLpa1 Receptor-dependent MechanismMedicineStem Cell Research	2010	45
Lysophosphatidic acid‐induced expression of periostin in stromal cells: Prognoistic relevance of periostin expression in epithelial ovarian cancer Kyung Un Choi, Jeong Sup Yun, Il Hwan Lee, International Journal of Cancer Stromal CellsLpa Receptor 1Epithelial Ovarian CancerMedicineCancer Growth	2010	44
The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients Yoon Ji Choi, Seung Tae Kim, Kyong Hwa Park, Medical Oncology Bone Morphogenic ProteinPathologyBronchial NeoplasmLung CancerMedicine	2011	37

Page 1